Lyell Immunopharma, Inc.
NASDAQ:LYEL
1.35 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0.13 | 84.683 | 10.65 | 7.756 | 0.657 |
| Cost of Revenue
| 20.25 | 16.467 | 14.535 | 7.475 | 0 |
| Gross Profit
| -20.12 | 68.216 | -3.885 | 0.281 | 0.657 |
| Gross Profit Ratio
| -154.769 | 0.806 | -0.365 | 0.036 | 1 |
| Reseach & Development Expenses
| 182.945 | 159.188 | 138.693 | 182.243 | 63.595 |
| General & Administrative Expenses
| 66.983 | 117.307 | 89.057 | 46.881 | 39.151 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 66.983 | 117.307 | 89.057 | 46.881 | 39.151 |
| Other Expenses
| 1.846 | 1.887 | -2.324 | -9.431 | -35.409 |
| Operating Expenses
| 247.138 | 276.495 | 225.426 | 219.693 | 102.746 |
| Operating Income
| -247.008 | -183.118 | -214.776 | -211.937 | -102.089 |
| Operating Income Ratio
| -1,900.062 | -2.162 | -20.167 | -27.326 | -155.387 |
| Total Other Income Expenses Net
| -11.077 | -178.364 | -35.443 | 7.465 | -27.288 |
| Income Before Tax
| -234.632 | -183.118 | -250.219 | -204.472 | -129.377 |
| Income Before Tax Ratio
| -1,804.862 | -2.162 | -23.495 | -26.363 | -196.921 |
| Income Tax Expense
| -10.53 | -178.364 | 35.282 | -5.939 | -8.121 |
| Net Income
| -234.632 | -4.754 | -285.501 | -198.533 | -121.256 |
| Net Income Ratio
| -1,804.862 | -0.056 | -26.808 | -25.597 | -184.56 |
| EPS
| -0.93 | -0.019 | -1.18 | -0.81 | -0.49 |
| EPS Diluted
| -0.93 | -0.019 | -1.18 | -0.81 | -0.49 |
| EBITDA
| -213.835 | -165.098 | -164.705 | -207.643 | -100.833 |
| EBITDA Ratio
| -1,644.885 | -1.95 | -15.465 | -26.772 | -153.475 |